Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
The Fund's Board of Trustees renewed an open-market share repurchase program authorizing purchases of up to 5% of outstanding common shares through June 30, 2027. While share repurchase programs are routine for closed-end funds seeking to manage discount-to-NAV dynamics, the renewal and authorization of a material repurchase capacity (5% of shares) would affect investor assessment of capital allocation and share price support. This does not fit neatly into the more specific event categories but represents a material corporate action disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 8.01
The Fund's Board of Trustees renewed an open-market share repurchase program authorizing purchases of up to 5% of outstanding common shares through June 30, 2027. While share repurchase programs are routine for closed-end funds seeking to manage discount-to-NAV dynamics, the renewal and authorization of a material repurchase capacity (5% of shares) would be material to investors assessing capital allocation and potential accretion/dilution. This does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), so "other_material" is most appropriate.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 7.01
Service Corporation International announced an increase to its share repurchase program by approximately $472 million, bringing total authorization to $600 million. While share repurchase programs are material to investors as they signal management's confidence in valuation and affect capital allocation, this disclosure does not fit neatly into the standard taxonomy categories (it is neither a dilutive issuance, M&A activity, nor executive compensation). The announcement reflects a significant capital allocation decision that would affect a reasonable investor's assessment of the company's financial strategy and shareholder returns.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 8.01
The filing discloses publication of a notice of an extraordinary general meeting of shareholders on June 11, 2026. While the Item 8.01 disclosure itself is minimal and does not specify the agenda or purpose of the meeting, an extraordinary (non-routine) shareholder meeting typically signals a material corporate event such as a major transaction, governance change, or other significant matter requiring shareholder approval. Without access to the attached exhibit detailing the meeting agenda, the most appropriate classification is "other_material" rather than a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 8.01
Bion extended a Memorandum of Understanding with Kimmeridge Energy Management for six months, preserving a Right of First Refusal (ROFR) that was originally granted in December 2025. While the extension itself is contractual in nature, the preservation of ROFR rights—which typically grant preferential acquisition or investment opportunities—could materially affect the company's strategic options and capital structure. The disclosure does not fit neatly into more specific categories (not M&A activity per se, not a financing event, not a routine administrative matter), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-11
Item 8.01
Terra Property Trust disclosed an extension of its previously announced Exchange Offer for senior notes maturing June 30, 2026, along with detailed cash flow projections for April–September 2026 revealing a potential liquidity shortfall depending on the exchange offer's success and timing of asset monetizations. The disclosure reflects material concerns about the company's near-term liquidity, ability to meet debt obligations, and dependence on the exchange offer and asset sales to address upcoming maturities.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Theriva Biologics announced publication of Phase 1 clinical trial results for VCN-01 in head and neck squamous cell carcinoma (HNSCC), including median progression-free survival and overall survival data, biomarker findings, and mechanistic insights. These clinical results are material to investor assessment of the company's pipeline and the program's viability.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 3.03
The company completed a redomestication from Delaware to Texas, approved by stockholders at the May 8, 2026 Annual Meeting, resulting in a material modification to shareholder rights due to the shift from Delaware law to Texas law governance. The redomestication did not change business operations, headquarters, management, or obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 5.03
The company effected a charter amendment implementing a name change, a material event affecting the registrant's corporate identity and public recognition. The name change was formally announced in the company's press release.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
Caterpillar announced a quarterly cash dividend increase from $1.51 to $1.63 per share, representing an approximately 8% increase that signals management confidence in cash generation.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
Vireo Growth Inc. announced and implemented a 30-for-1 share consolidation effective June 5, 2026, following shareholder approval and Board authorization. This material capital structure reorganization affects all shareholders' ownership percentages and voting rights.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 1.01
AECOM entered into a $500 million revolving credit facility with Bank of America on June 10, 2026, secured with leverage covenants including a 4.00x consolidated leverage ratio. This material financing arrangement affects the company's liquidity, financial flexibility, and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
OraSure announced FDA clearance of its Colli-Pee™ Dx Urine Collection Kit for use with Roche molecular diagnostic systems to detect four sexually transmitted infections. This is a material regulatory milestone that expands the company's product portfolio and market reach through a partnership with a major diagnostics company (Roche), but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or litigation). The disclosure warrants classification as a material product/regulatory event under "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 2.03
The filing discloses creation of a direct financial obligation under Item 2.03, incorporating Item 1.01 by reference; the specific nature of the obligation (debt, lease, contingent liability, or other commitment) cannot be determined without access to the referenced Item 1.01 content.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 3.03
Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01, 5.01, and 5.03; the specific nature of the modification cannot be reliably determined from the cross-references alone, though it likely relates to the merger, delisting, or change of control.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M&A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-11
Item 8.01
Enliven Therapeutics announced updated positive Phase 1 clinical trial data from the ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia, including key outcomes from an FDA End-of-Phase 1 meeting and selection of the 80 mg QD dose for Phase 3 development. This represents material clinical progress for the company's lead candidate that affects investor assessment of the pipeline and regulatory pathway.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 5.03
The company filed a Series P Certificate of Designation establishing the terms of a new preferred stock class with 8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections. These structural provisions create contingent obligations that could materially affect the company's capital structure and shareholder value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Broadcom announced the launch of cash tender offers for certain debt securities on June 11, 2026. While this is a material capital management activity that would affect investor assessment of the company's financial strategy and debt structure, it does not fit neatly into the more specific event categories (it is not a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, or dilutive equity issuance). Debt tender offers are material refinancing activities but lack a dedicated taxonomy category, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—it describes the mechanism and structure of consolidated obligations rather than disclosing a specific new debt issuance event. The prose emphasizes that Schedule A lists obligations "committed to be issued" and notes the FHLBank has not made materiality judgments on particular obligations. This appears to be a standing disclosure of the FHLBank's debt issuance framework rather than a discrete material event triggering Item 2.03, making it best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-11
Item 1.01
Badger Meter amended and extended its $150 million revolving credit facility, with a new maturity date of July 8, 2031. The amendment represents a material refinancing and extension of the company's existing credit facilities, affecting its capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
General Motors Financial Company closed a $1 billion public offering of senior notes due 2031 with net proceeds of approximately $993 million. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy—it is neither a merger/acquisition (ma_activity), a dilutive equity issuance (dilutive_issuance), nor a debt covenant breach (covenant_breach). The disclosure is a routine debt offering, which is material to investors but lacks the specific event-type indicators that would classify it as earnings_release, going_concern, or other defined categories.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Intuit issued $1.75 billion in aggregate principal amount of senior notes ($750M due 2031 at 4.950% and $1B due 2036 at 5.500%), with net proceeds of approximately $1.74 billion intended for general corporate purposes including potential refinancing of existing debt. While this is a material financing event affecting the registrant's capital structure and liquidity, it does not fit cleanly into the more specific event categories (not a dilutive equity issuance, not M&A activity, not a covenant breach or going-concern disclosure). The disclosure is routine debt issuance disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-11
Item 8.01
Seagate announced a redemption of $1 billion in 3.50% Exchangeable Senior Notes due 2028, with a redemption date of September 8, 2026. This debt management action affects the company's capital structure and involves convertible debt that may result in shareholder dilution through the exchange mechanism.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
The registrant announced a second quarter cash dividend of $0.45 per share via press release on June 11, 2026. While dividend declarations are routine for REITs like Chimera Investment Corp, they are material to investors as they directly affect shareholder returns and are a key metric for evaluating the company's financial health and distribution capacity. This does not fit the earnings_release category (which typically discloses quarterly/annual financial results) but represents a material capital allocation decision.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 2.03
Adial Pharmaceuticals guaranteed the Azora Notes upon closing of the merger, creating a direct financial obligation that arises from the material acquisition transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
The Board postponed the 2026 Annual Meeting scheduled for June 18, 2026, citing a need for "additional time to evaluate certain matters relating to the Annual Meeting and the business to be presented to stockholders." While the disclosure does not specify the underlying issues, the vague language about evaluating "certain matters" relating to both the meeting and business operations, combined with the decision to postpone without a rescheduled date, suggests potential material concerns that do not fit neatly into standard event categories. This is material to investors as it signals unspecified governance or operational issues requiring investigation.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
The Company discloses a material restructuring of a previously announced acquisition: the 2022 Agreement for an 80.1% equity stake in SMS is being superseded by a proposed direct asset acquisition of the Cross-Caribou mining asset. While no definitive agreement has been executed for the 2026 Asset Acquisition, the disclosure of this strategic pivot—from equity acquisition to asset acquisition—would affect a reasonable investor's assessment of the Company's M&A strategy and asset base. The event does not fit cleanly into ma_activity (no definitive agreement yet) but represents a material change in transaction structure that warrants disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 1.01
Melar Acquisition Corp. entered into a material definitive agreement with its sponsor for a promissory note of up to $1.5 million to fund working capital advances, bearing 17.5% interest with a conversion-to-warrant feature.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The disclosure describes the consummation of Tribeca Strategic Acquisition Corp.'s IPO on June 1, 2026, generating $140 million in gross proceeds from 14 million units at $10.00 per unit, plus concurrent private placement sales of $4.7 million. While this is a material capital-raising event affecting the registrant's financial position, it does not fit neatly into the standard 8-K taxonomy—it is neither a traditional earnings release, M&A activity, nor a financial restatement. As a SPAC IPO completion disclosure, it is material to investors but best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
This disclosure announces an update to the terms of a shareholder extension vote scheduled for June 16, 2026, specifically increasing the Sponsor's monthly contribution cap to the Trust Account from $40,000 to $80,000. While the filing relates to a shareholder meeting and proxy solicitation, the core event is a material amendment to the economic terms of the extension arrangement that affects shareholder value and redemption economics. This does not fit cleanly into shareholder_vote_results (which covers vote outcomes, not pre-vote amendments) or other standard categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The filing discloses completion of an IPO generating $172.5 million in gross proceeds and a concurrent private placement of warrants generating $3.6 million, with approximately $173.4 million placed in trust. While this is a material capital-raising event, it does not fit cleanly into the earnings_release or dilutive_issuance categories—it is a post-IPO confirmation of consummation rather than a prospective offering disclosure or earnings announcement. The event is material to investors but is best classified as other_material given the specific post-closing nature of the disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The filing discloses completion of an initial public offering (IPO) on June 5, 2026, generating $201.25 million in gross proceeds from the sale of 20.125 million units, plus a concurrent private placement of 540,000 units generating $5.4 million. While this is a material capital-raising event, it does not fit neatly into the standard 8-K taxonomy—it is neither a traditional earnings release, M&A activity, nor a dilutive issuance in the sense of a secondary offering by an already-public company. The disclosure is primarily confirmatory of an already-announced IPO and trust account establishment, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $30 million (two bonds: $15M at 4.625% due 12/28/2029 and $15M at 4.500% due 6/23/2031). While Item 2.03 typically signals covenant_breach or debt acceleration events, this filing describes routine debt issuance by a Federal Home Loan Bank in the capital markets—a core funding mechanism explicitly noted as "material to the Bank" but presented as ordinary business activity. The disclosure does not indicate a breach, acceleration, or triggering event; rather, it reports scheduled debt issuances. This does not fit cleanly into covenant_breach (no breach indicated) or the other specific event types, making other_material the most appropriate classification for a material debt issuance that falls outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the disclosure is primarily informational and regulatory in nature—explaining the structure, joint-and-several liability framework, and reporting methodology rather than announcing a specific new debt issuance event. The actual obligations are detailed in Schedule A (not provided here). This does not fit cleanly into covenant_breach (no violation alleged) or the more specific debt-related categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 2.03
This 8-K Item 2.03 discloses the issuance of consolidated obligations (debt securities) totaling approximately $775 million in principal across four separate issuances with trade dates of 06/08–06/09/2026. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the taxonomy does not include a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt obligations, but it does not fit cleanly into covenant_breach (no breach alleged), dilutive_issuance (debt, not equity), or ma_activity (no acquisition or merger). The event is routine debt financing for a Federal Home Loan Bank, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the issuance of Consolidated Bonds (debt securities) totaling approximately $92 million across six bond offerings with trade dates in June 2026. While Item 2.03 is technically designed for "creation of a direct financial obligation," the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure is routine debt issuance reporting rather than a discrete material event like a covenant breach or going-concern issue. This falls outside the more specific event categories and is best classified as other_material given the FHLB's own acknowledgment of materiality combined with the routine nature of the disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $195 million across six bond tranches with varying maturities (2027–2031) and coupon rates (4.02%–4.50%). While Item 2.03 typically signals covenant breaches or direct financial obligations under off-balance-sheet arrangements, this filing explicitly discloses routine debt issuance by a Federal Home Loan Bank in the ordinary course of business. The Bank notes that "consolidated obligations issuance is material to the Bank" but has not made materiality judgments on individual issuances. This is a material debt financing event, but it does not fit the specific taxonomy categories (covenant_breach implies default risk; ma_activity implies acquisition/disposition). The disclosure is material to investors assessing the Bank's capital structure and leverage, warranting classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $1.37 billion across five tranches with varying maturities and rate structures. While Item 2.03 typically signals covenant_breach or direct financial obligations of concern, this filing discloses routine debt issuances by a Federal Home Loan Bank in the ordinary course of business—a material but recurring funding activity. The disclosure emphasizes joint and several liability across all FHLBanks and provides detailed terms in Schedule A, but does not indicate a triggering event, breach, or acceleration of obligations that would warrant covenant_breach classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $5.555 billion across six separate debt securities issued in June 2026. While Item 2.03 is the designated item for debt creation, the taxonomy lacks a specific "debt_issuance" category; the event is material to investors as it represents significant new financial obligations and capital market activity, but does not fit cleanly into the provided event types (covenant_breach applies to violations, not new issuances). This is classified as other_material rather than covenant_breach, which is reserved for triggering events that accelerate obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling approximately $130 million across three separate issuances with maturities ranging from one to two years. While Item 2.03 is titled "Creation of a Direct Financial Obligation," the disclosure is routine debt issuance reporting by a government-sponsored enterprise (FHLB) rather than a triggering covenant breach or material financial stress event. The bonds are joint and several obligations of all FHLBanks and are not government-guaranteed, making this a material financial obligation that would affect investor assessment, but it does not fit the specific "covenant_breach" category which implies acceleration or distress.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $70 million ($50M + $20M par amounts) by the Federal Home Loan Bank of Dallas. While the filing itself emphasizes that the Bank "has not made a judgment as to the materiality of these consolidated obligation bonds," the issuance of debt securities is a material financial obligation that would affect a reasonable investor's assessment of the registrant's capital structure and leverage. However, this does not fit neatly into the more specific event categories (e.g., it is not a covenant breach, dilutive issuance, or M&A activity), making "other_material" the most appropriate classification for routine debt issuance disclosure under Item 2.03.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 8.01
The Board approved an interim dividend of $1.014 per ordinary share payable in July 2026, representing a direct return of capital to shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 5.03
The Board adopted amendments to the Company's Bylaws that materially reduce the quorum requirement from a majority to one-third of voting power and change the voting standard for non-director matters from a majority of shares present to a majority of votes cast. These governance changes lower the threshold for stockholder action and could affect the ease with which future proposals pass, making them material to investor assessment of corporate control dynamics, though they do not fit the more specific event categories in the taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 8.01
The Board authorized a share repurchase program for up to 300,000 shares on June 10, 2026. The authorization signals management confidence in the company's valuation and reflects capital allocation decisions, though specific timing and pricing details were not disclosed.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
The filing discloses completion of a 1-for-5 reverse stock split effective June 11, 2026, reducing issued shares from approximately 367.7 million to 73.9 million and authorized shares from 5 billion to 1 billion. While reverse splits are routine capital structure adjustments, this one is material to investors as it affects share count, trading symbols, and CUSIP numbers. The event does not fit neatly into the specific taxonomy categories (not an earnings release, executive change, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
The filing discloses a press release announcing 30-day results from the CGUARDIANS II clinical trial of the CGuard Prime 80 cm implant for TCAR procedures. This is a clinical trial result disclosure under Item 7.01 (Regulation FD Disclosure). While clinical trial results can be material to investors in medical device companies, this does not fit neatly into the standard taxonomy categories (not an earnings release, not a restatement, not litigation, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
The filing discloses entry into a material supply agreement (Item 1.01) between TechForce Robotics (a wholly-owned subsidiary) and Jiun Jiang Enterprise for manufacturing robotic systems. While this is a supply/manufacturing agreement rather than a traditional M&A transaction, the three-year initial term with auto-renewal, IP licensing framework, and strategic manufacturing partnership suggest materiality. However, the lack of financial terms, deal value, or strategic context makes it difficult to assess whether this rises to the level of a traditional "material acquisition" or is better classified as a significant operational/commercial arrangement outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
The filing discloses a one-for-ten reverse stock split of Shuttle Pharmaceuticals' common stock, effective June 11, 2026, authorized by stockholders at the May 21, 2026 annual meeting and implemented by board action on June 1, 2026. While reverse stock splits are typically administrative in nature, this event is material to investors as it affects share count, exercise prices of warrants and convertible securities, and trading mechanics on Nasdaq. The event does not fit neatly into the specific taxonomy categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote results, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →